Search Results for: Enlivex

Funds for immunotherapy treatment

I reported previously (three times) on Israel’s Enlivex and its Allocetra / Apocell treatment to prevent Graft vs Host Disease – a common problem after bone marrow transplants.  Elivex has just received $8 million of funding which will help it … Continue reading

Posted in Economy & Business | Leave a comment

Graft-vs-Host disease treatment gets boost

The European Medicines Agency (EMA) has granted Israeli biotech Enlivex “orphan” status for its ApoCell treatment to prevent Graft-vs-Host Disease.  It will speed up development of the Israeli innovation that stops rejection of transplanted cells and bone marrow. http://www.nasdaq.com/press-release/enlivex-granted-eu-orphan-drug-designation-for-lead-product-apocell-for-graftversushost-disease-20150126-00574

Posted in Israel's Medical Achievements | Leave a comment

Bone marrow treatment gets boost

In January I mentioned Apocell from Israeli biotech Enlivex, which prevents GVHD rejection of bone marrow transplants. Now, the treatment has received US FDA “orphan” status due to its importance and lack of alternatives for treating the unwanted autoimmune response. … Continue reading

Posted in Israel's Medical Achievements | Leave a comment

Israeli treatment helps bone marrow transplants

Israeli biotech Enlivex has developed a treatment called ApoCell that triggers a response from the immune system to reduce adverse reactions during bone marrow transplants. It prevents Graft vs Host Disease (GVHD), which affects around 70% of transplant patients. http://unitedwithisrael.org/enlivex-innovation-leads-to-effective-new-cancer-treatment/ … Continue reading

Posted in Israel's Medical Achievements | Leave a comment